Abstracts tagged "Myopathies"

Abstract Number: 2670 • ACR Convergence 2024
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Cecilia Leijding¹, Suchada Kaewin², Kristofer Andreasson¹, Tomas Schiffer¹, Angeles Galindo-Feria³, Begum Horuluoglu¹, Mattias Carlstrom¹, Stefano Gastaldello¹, Helene Alexanderson⁴, Ingrid Lundberg⁵ and Daniel Andersson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Solna, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
Abstract Number: 1965 • ACR Convergence 2024
Artificial Intelligence Assisted Interpretation of Lung Ultrasound Imaging for the Detection of Interstitial Lung Disease
Robert Fairchild¹, Diane Mar², Mariani Deluna³, Matthew Baker⁴, suzanne Tamang⁵, Henry Guo³, David Fiorentino⁴ and Lorinda Chung⁶, ¹Stanford University, San Francisco, CA, ²VA Palo Alto / Stanford, Palo Alto, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA, ⁵Stanford University, Atherton, CA, ⁶Stanford University, Woodside, CA
Background/Purpose: Interstitial lung disease (ILD) is a serious complication of SSc and inflammatory myopathy (IM), necessitating accurate and early detection for improved outcomes. Lung ultrasound…
Abstract Number: 1168 • ACR Convergence 2023
Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
Sonali Narain¹, Can Hu², Michael Liu¹, Himanshu Vashistha¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: ILD is a major cause of morbidity and mortality in IIM. The diagnosis and progression of ILD often relies on high resolution computed tomography…
Abstract Number: 1971 • ACR Convergence 2023
Muscle Pathology in Patients with Primary Biliary Cholangitis
Jose Cesar Milisenda¹, Iago Pinal-Fernandez², Katherine Pak², Maria Casal-Dominguez³, Yaiza Duque-Jaimez⁴, Gloria Garrabou¹, Sandra Muñoz-Braceras⁵, Mariona Guitart-Manpel¹, Jose Jiram Torres-Ruiz⁵, Ester Tobias⁴, Maria Dolores Cano⁴, Iban Aldecoa⁴, Josep Maria Grau¹ and Andrew Mammen³, ¹Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, ²National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects middle-aged women. It is characterized by elevated serum alkaline phosphatase levels,…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
Abstract Number: 1172 • ACR Convergence 2023
Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Hideaki Tsuji¹, Fabricio Espinosa-Ortega², Maryam Dastmalchi², Ingrid Lundberg² and Karin Lodin³, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden
Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
Abstract Number: 2461 • ACR Convergence 2023
Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies
Iago Pinal-Fernandez¹, Jose Cesar Milisenda², Katherine Pak¹, Sandra Muñoz-Braceras³, Maria Casal-Dominguez³, Jose Jiram Torres-Ruiz³, Stefania Dell´Orso⁴, Faiza Naz⁴, Gustavo Gutierrez-Cruz⁴, Yaiza Duque-Jaimez², Ana Matas-Garcia², Joan Padrosa⁵, Francesc J Garcia-Garcia², Mariona Guitart-Manpel², Gloria Garrabou², Ernesto Trallero-Araguas⁶, Brian Wallit⁷, Julie Paik⁸, Jemima Albayda⁸, Lisa Christopher-Stine⁸, Tom Lloyd⁹, Josep Maria Grau², Albert Selva-O’Callaghan⁶ and Andrew Mammen¹⁰, ¹National Institutes of Health, Bethesda, MD, ²Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, ³Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵CIBERER, Barcelona, Spain, Barcelona, Spain, ⁶Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁷National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, ⁸Johns Hopkins University, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰NIH, Bethesda, MD
Background/Purpose: Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (AS), and inclusion body myositis (IBM). Myositis-specific autoantibodies…
Abstract Number: 0290 • ACR Convergence 2023
Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy
Zhao Peng¹, Yanhong Wang², Ning Liu³, Shuang Zhou⁴, Jiuliang zhao¹, Dong Xu⁵, Mengtao Li⁶, chanyuan wu⁴ and Qian Wang⁴, ¹Peking Union Medical College, Beijing, China, ²Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, HongKong, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: To investigate the health-related quality of life (HR-QoL), work productivity and activity impairment, and associated factors among patients with idiopathic inflammatory myopathy (IIM). Methods:…
Abstract Number: 1174 • ACR Convergence 2023
Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
Thomas Khoo¹, Xia Lyu², James Lilleker¹, Janine Lamb¹, Vidya Limaye³ and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴The University of Manchester, Sale, United Kingdom
Background/Purpose: Immune-mediated necrotising myopathy (IMNM) is a rare complication of statin therapy, associated with the development of anti-HMGCR antibodies directed against the enzymatic target of…
Abstract Number: 2462 • ACR Convergence 2023
Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications
Jorge Armando Gonzalez-Chapa¹, Jemima Albayda², Begum Horuluoglu³, Despina Michailidou¹, Marina Barguil Macedo¹, Lisa Christopher-Stine², Ingrid Lundberg⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Johns Hopkins University, Baltimore, MD, ³Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work…
Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…
Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Yusra Hasan¹, Katharine Ching Chung², Dana Ascherman³, Siamak Moghadam-Kia⁴, Chester V. Oddis³ and Rohit Aggarwal³, ¹CHI Health Creighton University Medical Center, Omaha, NE, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
Abstract Number: 2463 • ACR Convergence 2023
Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
Jule Taubmann¹, Johannes Knitza², Fabian Müller³, Sebastian Boeltz¹, Simon Voelkl⁴, Michael Aigner⁴, Arnd Kleyer⁵, Ioanna Minnopoulou¹, Regina Gary⁴, Sascha kretschmann⁴, Andreas Mackensen⁴ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ³Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Antisynthetase syndrome (ASS) can be very severe affecting the lungs, the skin and the joints next to the muscles. ASS can take a refractory…
Abstract Number: 0295 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies
Cody Bruggemeyer¹, Sanket Shah², Didem Saygin³ and Mike Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis Jirovecii Pneumonia (PJP) is an opportunistic fungal infection with high morbidity and mortality rates. Few studies to date have assessed the incidence of…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].